Thanks JTFM. This is very encouraging to hear. Much better than the recurring story of price erosion of the generics.
I thought you would like the reference below. You will recognize the author. He is the President of Pantarhei Biosciences and developer of the Pill Plus. It looks like he is responding to a separate article from Susan Davis with a letter.
The article is behind a pay wall. It is fascinating to see all of the intersections here. I suspect it is a positive letter since Susan Davis' article speaks to the certainties and uncertainties of testosterone use for women. I will keep checking to see if it becomes available.